To more accurately account for this richer picture of human genomic variation, Thermo Fisher Scientific has launched the new Axiom™ PangenomiX Array*, its largest and most ethnically diverse array to date, offering optimal genetic coverage for population scale disease studies and pharmacogenomic research. The high-throughput array is designed to advance disease risk and detection research, population-scale disease research programs, ancestry and wellness testing, drug efficacy testing, and drug development research. With its depth and breadth of coverage, the PangenomiX Array offers a cost-effective, accurate and reproducible solution that builds on our 30+ years in dedicated microarray research and testing with the goal of powering research that helps people live longer, healthier lives.”To learn more about the PangenomiX Array, please visit our website: www.thermofisher.com/PangenomiX*The PangenomiX Array is for research use only. About Thermo Fisher ScientificThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Source: New York Times January 08, 2024 09:51 UTC